News

pharmaphorum3d
Enhertu poised to move first line in HER2+ breast cancer
Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...
MedCity News4d
AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy
AstraZeneca and Daiichi Sankyo said the improvement in progression-free survival was observed across all pre-specified patient subgroups that received Enhertu paired with Perjeta. On the key ...
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...
pharmaphorum3d
Seagen wins Enhertu patent dispute with Daiichi Sankyo
A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer ... targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...